New Nexavar Data Presented In Multiple Tumor Types At 44th American Society Of Clinical Oncology Annual Meeting

WAYNE, N.J. and EMERYVILLE, Calif. -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the presentation of new clinical data from the early clinical trials in the development program for Nexavar(R) (sorafenib) tablets in multiple tumor types including lung, thyroid, gastric and ovarian cancers. Nexavar is currently approved in more than 40 countries for the treatment of patients with unresectable liver cancer and in more than 70 countries for the treatment of patients with advanced kidney cancer. "Findings from these early phase studies are encouraging and will be integral in informing our development strategies for the ongoing Nexavar clinical program," said Henry Fuchs, MD, executive v...